The first vaccine developed one hundred percentE

Written on August 24th, 2010 by admin

The first vaccine developed one hundred percent effective against hepatitis E.

A phase III study conducted among nearly 100,000 volunteers have shown that the first vaccine developed to prevent the development of hepatitis E-called 'HEV239'-has an efficiency close to one hundred percent of the cases and causes few side effects and mild similar to those of other vaccines, such as influenza.

The vaccine has also proven to be effective with only two doses, rather than the three that, gaia gold, were provided The research, published in the edition 'on line' of the journal The Lancet, took as a sample of 97 356 men and women Jiangsu (China ) between 16 and 65 years were divided into two groups: one received intramuscular vaccine for hepatitis E in three doses (the second month and the third at six months) and another that received placebo instead.

, tera gold, Among the participants, 11 165 were carriers of hepatitis E antibody, and of these, 5285 (47%) proved to be seropositive for this virus. The entire sample was subjected to a medical monitoring for 19 months. Thus, for 12 months and 30 days that have passed since the third dose, 15 patients in the placebo group developed the, free mmorpg game, disease compared to none of those receiving the 'HEV239' (100% efficiency).

"The vaccine has also proven equally effective in all subgroups of age and sex and even proved effective with only two doses, which will allow people who need to go to endemic areas to secure adequate protection against the virus without having to wait for the third dose at six months, "says study director, Dr. Ning-Shao Xia, Institute of Diagnostics and Vaccine Development in Xiamen (China).

Further studies are required to verify the benefits of the vaccine in pregnant women under 15 years and over 65 In this sense, Chinese researchers report that individuals with chronic liver disease should have priority in receiving the vaccine for their increased vulnerability to HIV. In the study did not include patients with this profile, so the authors suggest that prior to marketing more data are needed and further studies of efficacy and safety of the vaccine in this subgroup.

Also, "the study we have shown that the vaccine is effective and well tolerated in the general adult population, but further studies are needed to verify the benefits of the vaccine in pregnant women and people under 15 years and over 65" says Dr. Xia.

• Tourist Bus in Philippines capital Manila kidnappe